Christine A. White

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

M. S. Czuczman, A.J. Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 1999 · 856 citations

Medicine, Hematology, Oncology +15

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Thomas A. Davis, Antonio J Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 2000 · 689 citations

Pharmacy, Hematology, Pharmacotherapy +15

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

DG Maloney, A.J. Grillo-López, David Bodkin et al. · Journal of Clinical Oncology · 1997 · 638 citations

Pharmacy, Hematology, Pharmacokinetics +17